Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.25 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/25/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (STDAF) Key Developments

Stada-Arzneimittel AG Reports Earnings Results for the Second Quarter Ended June 30, 2015

Stada-Arzneimittel AG reported earnings results for the second quarter ended June 30, 2015. The company has reported that earnings after taxes distributable to shareholders for the second quarter ended June 30, 2015 were EUR 32.41 million, or EUR 0.53 per diluted share, compared to EUR 31.77 million, or EUR 0.52 per diluted share, for the same quarter ended June 30, 2014. Sales for the second quarter ended June 30, 2015 were EUR 539.71 million, compared to EUR 495.37 million for the same quarter ended June 30, 2014.

Stada Arzneimittel Reports Sales Results for the First Half of 2015

Stada Arzneimittel reported sales results for the first half of 2015. For the period, the company's sales rise of 2% year on year to EUR 1,025.9 million. The firm benefited from an improved performance in the second quarter with a positive sales performance in Central Europe and Asia-Pacific & MENA.

Gedeon Richter Plc. Signs License and Distribution Agreement with Stada Arzneimittel AG to Commercialize Richter's Biosimilar Pegfilgrastim in Europe

Gedeon Richter Plc. and STADA Arzneimittel AG announced that the two companies have signed a license and distribution agreement to commercialize Richter's biosimilar Pegfilgrastim in Europe. According to the agreement STADA receives non exclusive distribution rights for the area of geographical Europe (excluding Russia), while Richter retains its rights to distribute and market biosimilar Pegfilgrastim worldwide. Under the terms of the agreement in addition to a payment on the event of signing the contract, STADA is obliged to make further payments each depending on the progress of the project. With the start of marketing, STADA will report the resulting sales and make license related further payments to Richter.

Stada-Arzneimittel AG Reports Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Fiscal 2015

Stada-Arzneimittel AG reported earnings results for the six months ended June 30, 2015. For the period, the company reported group sales of EUR 1,025.9 million against EUR 1,002.8 million a year ago. EBITDA was EUR 181.4 million against EUR 192.1 million a year ago. EBITDA, adjusted was EUR 189.2 million against EUR 208.3 million a year ago. Net income was EUR 53.6 million against EUR 66.8 million a year ago. Net income, adjusted was EUR 85.0 million against EUR 90.1 million a year ago. Earnings per share were EUR 0.88 against EUR 1.11 a year ago. Earnings per share adjusted were EUR 1.39 against EUR 1.49 a year ago. Cash flow from operating activities amounted to EUR 40.4 million against EUR 61.8 million a year ago. Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals amounted to EUR 5.7 million against EUR 28.3 million a year ago. In the current financial year, the group has been confronted with very difficult framework conditions, especially due to the ongoing CIS crisis. In light of this, for the outlook for 2015, the Executive Board expects to be able to achieve slight growth in Group sales adjusted for currency and portfolio effects. Due to the development of the Russian ruble and increased risks in connection with consumer mood and the general market situation, however, it anticipates a decreased earnings contribution from Russia. Taking these developments into account and based on currency relations at the time the preliminary outlook was published, the Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3 in 2015. For the full year the company expects tax rate between 24% and 26%.

Stada-Arzneimittel Not Approached For Sale

Stada-Arzneimittel AG (DB:SAZ) has not been approached by potential buyers, Chief Executive Officer Hartmut Retzlaff said.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAF:US $34.25 USD 0.00

STDAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 4,181 INR +50.65
Impax Laboratories Inc $42.98 USD -0.99
Merck KGaA €84.73 EUR -0.35
Medicines Co/The $33.02 USD +1.27
UCB SA €67.20 EUR -0.56
View Industry Companies
 

Industry Analysis

STDAF

Industry Average

Valuation STDAF Industry Range
Price/Earnings 36.3x
Price/Sales 0.9x
Price/Book 1.9x
Price/Cash Flow 37.0x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.